NO964793L - Fremgangsmåte ved anvendelse av peroksynitrit dekomponeringskatalysatorer, og farmasöytiske sammensetninger for disse - Google Patents

Fremgangsmåte ved anvendelse av peroksynitrit dekomponeringskatalysatorer, og farmasöytiske sammensetninger for disse

Info

Publication number
NO964793L
NO964793L NO964793A NO964793A NO964793L NO 964793 L NO964793 L NO 964793L NO 964793 A NO964793 A NO 964793A NO 964793 A NO964793 A NO 964793A NO 964793 L NO964793 L NO 964793L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
complex
decomposition
decomposing
decomposition catalysts
Prior art date
Application number
NO964793A
Other languages
English (en)
Norwegian (no)
Other versions
NO964793D0 (no
Inventor
Michael Keith Stern
Daniela Salvemini
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of NO964793D0 publication Critical patent/NO964793D0/no
Publication of NO964793L publication Critical patent/NO964793L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO964793A 1994-05-13 1996-11-12 Fremgangsmåte ved anvendelse av peroksynitrit dekomponeringskatalysatorer, og farmasöytiske sammensetninger for disse NO964793L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24249894A 1994-05-13 1994-05-13
PCT/US1995/005886 WO1995031197A1 (en) 1994-05-13 1995-05-09 Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor

Publications (2)

Publication Number Publication Date
NO964793D0 NO964793D0 (no) 1996-11-12
NO964793L true NO964793L (no) 1997-01-06

Family

ID=22915009

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964793A NO964793L (no) 1994-05-13 1996-11-12 Fremgangsmåte ved anvendelse av peroksynitrit dekomponeringskatalysatorer, og farmasöytiske sammensetninger for disse

Country Status (13)

Country Link
EP (1) EP0758892A1 (zh)
JP (1) JPH10500671A (zh)
CN (1) CN1222286C (zh)
AU (1) AU709553B2 (zh)
BR (1) BR9507643A (zh)
CA (1) CA2189528A1 (zh)
CZ (1) CZ323496A3 (zh)
FI (1) FI964537A (zh)
HU (1) HUT76327A (zh)
NO (1) NO964793L (zh)
NZ (1) NZ285648A (zh)
PL (1) PL317192A1 (zh)
WO (1) WO1995031197A1 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
AU3758695A (en) * 1994-09-20 1996-04-09 Duke University Oxidoreductase activity of manganic porphyrins
JP2001521939A (ja) 1997-11-03 2001-11-13 デューク・ユニバーシティー 置換されたポルフィリン類
JP4648542B2 (ja) 1998-04-24 2011-03-09 デューク ユニバーシティ 置換ポルフィリン
WO2000009111A2 (en) * 1998-08-11 2000-02-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibitors of amyloid formation
IL126953A0 (en) * 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
EP1013272A1 (en) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Manipulation of the activity of a nitric oxide radical production pathway for the treatment of diseases associated with the presence of oxygen free radicals
WO2000043395A1 (en) 1999-01-25 2000-07-27 National Jewish Medical And Research Center Substituted porphyrins
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
FR2806911B1 (fr) * 2000-03-28 2003-01-10 Univ Rene Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
ES2330728T3 (es) * 2001-01-19 2009-12-15 National Jewish Health Medicamento para proteccion en radioterapia.
AU2002312194B8 (en) 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
JP2006501163A (ja) 2002-06-07 2006-01-12 デューク・ユニバーシティー 置換ポルフィリン
DE10240343A1 (de) * 2002-08-27 2004-03-11 Schering Ag Peroxynitrit-Umlagerungskatalysatoren
US6946466B2 (en) * 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US7705040B2 (en) * 2005-10-07 2010-04-27 The University Of Hong Kong Reagents for highly specific detection of peroxynitrite
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
WO2008094222A2 (en) 2006-10-06 2008-08-07 Trustees Of Princeton Porphyrin catalysts and methods of use thereof
AU2008293376B2 (en) * 2007-08-28 2013-07-11 Technion Research & Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
RU2506083C2 (ru) 2008-05-23 2014-02-10 Нэшнл Джуиш Хелт Способ лечения поражений, ассоциированных с воздействием алкилирующих веществ
AU2014374361B9 (en) 2013-12-31 2019-07-04 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
RU2557655C1 (ru) * 2014-06-10 2015-07-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ФГБОУ ВПО "ИГХТУ") Никелевый комплекс 5,10,15,20-тетракис[3',5'-ди(2"-метилбутилокси)фенил]-порфина, проявляющий свойство стационарной фазы для газовой хроматографии
CN107573259A (zh) * 2017-09-25 2018-01-12 沅江华龙催化科技有限公司 一种金属卟啉催化芳香烯烃合成芳香腈的方法
EP4059496A1 (en) * 2021-03-18 2022-09-21 Institut Pasteur Mntbap and m(iii) n-substituted pyridylporphyrins (mnps) for use in reversing sepsis-induced microglial cells alteration(s), associated long-term cognitive impairment, and/or for treating sepsis or sepsis-associated encephalopathy (sae), and/or related short and/or long-term symptoms or complications thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0210351B1 (en) * 1985-04-30 1993-07-21 Nippon Petrochemicals Co., Ltd. Use of porphyrin derivatives in the detection and treatment of tumours
DE3688253T2 (de) * 1986-01-02 1993-09-02 Univ Toledo Herstellung und verwendung von purpurinen, chlorinen und purpurin und chlorin enthaltenden zubereitungen.
US4866054A (en) * 1986-05-13 1989-09-12 Chai-Tech Corporation Antioxidant metallo-organic treatment of inflammation
JPH02501740A (ja) * 1987-09-08 1990-06-14 ザ ロックフェラー ユニバーシティ 腫瘍治療における毒性作用を消去するためのメタロポルフィリンの使用
ATE146508T1 (de) * 1990-11-02 1997-01-15 Zeneca Ltd Polysubstituierte phthalocyanine
CA2096333A1 (en) * 1990-11-14 1992-05-15 Joseph S. Beckman Compositions for reducing oxidative injury
FR2676738B1 (fr) * 1991-05-22 1995-05-05 Ir2M Nouveau derive organique de metal de transition a structure porphyrinique, composition therapeutique le contenant, en particulier a activite hypoglycemiante.
GB9111689D0 (en) * 1991-05-31 1991-07-24 Johnson Matthey Plc Gallium compounds
JP3155552B2 (ja) * 1991-07-19 2001-04-09 モンサント カンパニー 超酸化物の不均斉変化に有効な触媒としての窒素含有−大環状リガンドのマンガン錯体
EP0614361A4 (en) * 1991-11-25 1994-09-21 Albion Int Composition and method for reducing free radical cellular oxidative stress in warm-blooded animals.
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions

Also Published As

Publication number Publication date
HUT76327A (en) 1997-08-28
NZ285648A (en) 1999-08-30
NO964793D0 (no) 1996-11-12
CZ323496A3 (en) 1997-10-15
PL317192A1 (en) 1997-03-17
JPH10500671A (ja) 1998-01-20
CN1222286C (zh) 2005-10-12
AU709553B2 (en) 1999-09-02
CN1152871A (zh) 1997-06-25
FI964537A (fi) 1997-01-10
WO1995031197A1 (en) 1995-11-23
FI964537A0 (fi) 1996-11-12
EP0758892A1 (en) 1997-02-26
BR9507643A (pt) 1997-09-23
CA2189528A1 (en) 1995-11-23
AU2512095A (en) 1995-12-05
HU9603140D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
NO964793L (no) Fremgangsmåte ved anvendelse av peroksynitrit dekomponeringskatalysatorer, og farmasöytiske sammensetninger for disse
DE59310310D1 (de) 3-,8-substituierte deuteroporphyrinderivate, diese enthaltende pharmazeutische mittel und verfahren zu ihrer herstellung
EP0952773A4 (en) METHOD AND COMPOSITION FOR PREVENTING AND TREATING DISEASES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE59409568D1 (de) Wirkstoffe und gas enthaltende mikropartikel
DE69737510D1 (de) Verwendung eines unverkapselten anti-krebs-wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation
EP0831832A4 (en) METHODS FOR CONTROLLING INFECTIOUS DISEASES USING DICATIONIC BIS-BENZIMIDAZOLES
UA32429C2 (uk) Засіб для лікування нетримання сечі
NO973231L (no) Nye forbindelser
PL323046A1 (en) Procedures related to arterio-vascular and vascular transplants: method and compositions
ATE300288T1 (de) Zusammensetzung enthaltend insulin- sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
GR3031241T3 (en) Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
HK1037142A1 (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
WO2001030335A3 (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
MD2196B2 (ro) Criptoficine, procedeu de obţinere, compoziţii farmaceutice pe baza acestora, metodă de inhibare a proliferării celulelor mamiferelor şi metodă de atenuare a stării patologice cauzate de hiperproliferarea celulelor mamiferelor
HK1069327A1 (en) Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
BG105275A (en) Tan-1057 derivatives
ATE184484T1 (de) Wirkstoffe zur behandlung von suchterkrankungen
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
HU9201799D0 (en) New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
Lis-Balchin et al. A study of the changes in the bioactivity of essential oils used singly and as mixtures in aromatherapy
MX9605560A (es) Metodos de uso para catalizadores de descomposicion de peroxinitrito y composiciones farmaceuticas para los mismos.
DE4493859D2 (de) Estriol enthaltendes hormonales Mittel zur Prophylaxe und Behandlung arterieller Erkrankungen beim Mann, Verfahren zu seiner Herstellung und dessen Verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application